8-K: NanoVibronix Secures $8 Million in Initial Private Placement, Issues Convertible Preferred Stock and Warrants

NanoVibronix, Inc. has completed an initial private placement raising $8 million through the sale of Series H Convertible Preferred Stock and warrants, with proceeds earmarked for debt redemption and working capital.

Summary

• NanoVibronix, Inc. entered into a Securities Purchase Agreement on July 18, 2025, with an institutional investor for a private placement.
• The Initial Closing occurred on July 22, 2025, generating aggregate gross proceeds of $8,000,000.
• In the Initial Closing, the company sold 8,889 shares of newly-designated Series H Convertible Preferred Stock (Stated Value: $1,000 per share, total $8,888,889) and warrants to acquire up to 4,678,363 shares of Common Stock.
• The initial conversion price for the Preferred Stock is $1.01 per share, and the exercise price for the Warrants is $2.25 per share.
• The company intends to use $5,000,000 of the net proceeds from the Initial Closing to redeem certain outstanding shares of its Series X Preferred Stock, with the balance for working capital purposes.
• A second closing is planned for an additional 2,222 shares of Preferred Stock with a total stated value of $2,222,222, subject to customary closing conditions.
• The investor has a right, but no obligation, to purchase up to an aggregate of $44,000,000 stated value of additional Preferred Stock for 36 months from the effective date of the resale registration statement.
• Additional Preferred Stock will have an initial conversion price equal to 85% of the arithmetic average of the three lowest VWAPs during the ten trading days prior to the investor's exercise of such right.
• The Preferred Stock carries cumulative dividends at 9% per annum of the Stated Value, payable in Common Stock upon conversion, and has a liquidation preference over Junior Securities.
• Warrants are exercisable on the Shareholder Approval Date and expire 18 months thereafter.
• Shareholder approval is required under Nasdaq Stock Market Rule 5635(d) for the issuance of Common Stock exceeding 19.99% of outstanding shares at prices below the Minimum Price; the company must hold meetings every four months until approval is obtained.
• The company will file a resale registration statement for the Common Stock underlying the Preferred Stock and Warrants.

Sentiment

Score: 6

Explanation: The company successfully secured significant capital, which is positive for liquidity and debt reduction. However, the terms involve substantial potential dilution and ongoing obligations, which could weigh on existing shareholders.

Positives

• Secured $8,000,000 in gross proceeds from the initial closing, providing immediate capital infusion.
• A significant portion of the proceeds ($5,000,000) is allocated to redeem Series X Preferred Stock, which can improve the company's balance sheet and reduce certain preferred obligations.
• The investor has an option for substantial future investment (up to $44,000,000 stated value), indicating potential long-term financial support.
• The Preferred Stock includes anti-dilution provisions and a liquidation preference, offering some protection to the new investors.

Negatives

• The issuance of convertible preferred stock and warrants introduces significant potential for dilution to existing common shareholders.
• Full conversion and exercise of the securities are contingent on obtaining shareholder approval, which introduces uncertainty and requires ongoing effort.
• The Preferred Stock pays cumulative dividends at 9% per annum, payable in Common Stock, which will further contribute to dilution.
• The company is prohibited from certain equity issuances, including Variable Rate Transactions, for a specified period, which could limit future financing flexibility.

Risks

• Significant dilution of existing common shareholders' equity and voting power upon conversion of Preferred Stock and exercise of Warrants.
• Failure to obtain required shareholder approval could limit the company's ability to issue all underlying shares, potentially impacting its financial flexibility and relationship with the investor.
• Market price volatility of the Common Stock could affect the value of the Preferred Stock and Warrants, especially given the cashless exercise option and dividend payment in stock.
• The company's ability to maintain compliance with Nasdaq listing requirements, particularly regarding shareholder approval and share reservation, poses an ongoing challenge.

Future Outlook

The company plans to use the capital raised for the redemption of Series X Preferred Stock and for working capital. It is committed to seeking shareholder approval for the full issuance of shares underlying the new securities and will file a resale registration statement. The institutional investor retains a significant option for future investment, potentially providing additional capital to the company.

Industry Context

N/A

Corporate Governance

Related Party Transactions

• $5,000,000 of initial net proceeds and a portion of future additional investment proceeds are allocated to redeem Series X Preferred Stock held by Alpha Capital Anstalt (Alpha).

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the issuance of convertible preferred stock and warrants, especially if converted/exercised at lower prices. Existing common shareholders' voting power could be diluted upon full conversion.
• Creditors: The use of proceeds to redeem Series X Preferred Stock may improve the company's balance sheet by reducing certain preferred obligations, potentially strengthening its financial position.
• Investors (Purchasers): Gain significant equity and potential future investment rights, with anti-dilution protections and a liquidation preference, providing a structured investment opportunity.

Next Steps

• Hold a meeting of stockholders to seek approval for the issuance of Common Stock in excess of 19.99% of outstanding shares at prices below the Minimum Price, and hold subsequent meetings every four months if approval is not obtained.
• File a resale registration statement on Form S-3 (or other appropriate form) as soon as reasonably practicable for the Underlying Shares and Warrant Shares.
• Maintain a reserve of Common Stock for issuance upon conversion/exercise of the Preferred Stock and Warrants.
• Maintain listing of Common Stock on the Trading Market.
• Potentially conduct a second closing for additional Preferred Stock and Warrants, subject to conditions.
• Investor may exercise additional investment rights for up to $44,000,000 stated value of Preferred Stock over 36 months.

Key Dates

Recommendation

While the capital raise provides much-needed liquidity and addresses some preferred debt, the significant potential for dilution from the convertible preferred stock and warrants, coupled with the ongoing need for shareholder approval for full conversion, creates uncertainty. Investors should hold to monitor the company's execution of its strategic plan, the impact of dilution, and the outcome of the shareholder vote before making further investment decisions.

Keywords

NanoVibronix, NAOV, Private Placement, Convertible Preferred Stock, Warrants, Equity Financing, Capital Raise, SEC Filing, 8-K, Debt Redemption, Working Capital, Dilution, Shareholder Approval